Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

SPCs outlive patent protections in 91% of cases, new report reveals
Pharma
Supplementary protection certificates outlive medicinal patents in more than nine in ten cases, a new report has found.   24 June 2021
SCOTUS won’t resuscitate Amarin’s Vascepa patents
Pharma
Amarin has failed to persuade the US Supreme Court to consider reviving six patents on the heart medicine Vascepa, allowing generic drugmakers Hikma Pharmaceuticals and Dr. Reddy’s Laboratories to roll out copycat products.   22 June 2021
Allergan’s Forest to face jury in antitrust suit over Alzheimer drug
Pharma
Allergan subsidiary Forest Laboratories will have to argue its case before a jury over claims that it used pay-for-delay deals to keep generic copies of blockbuster Alzheimer drug, Namenda, from the marketplace.   15 June 2021
Pharma
Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.   7 June 2021
Biotech
A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.   1 June 2021
Europe
The University of California Berkeley has lost a CRISPR patent in Europe in the latest twist in the long-running IP saga over the gene-editing technology.   25 May 2021
Biotech
A Novartis unit, Sandoz, has failed to persuade the US Supreme Court to review two Amgen-owned patents on the rheumatoid arthritis drug Enbrel (etanercept).   18 May 2021
Pharma
The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid.   13 May 2021
Pharma
India-based generics drug maker Dr. Reddy's Laboratories has entered into a voluntary licensing agreement with Eli Lilly to expand access to COVID-19 treatment in India.   13 May 2021
Pharma
MSD, known as Merck in the US and Canada, has prevailed against a bid by Mylan Pharmaceuticals and other generic drug makers to invalidate a diabetes treatment patent.   11 May 2021

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.